Latest market price
26.17
+0.57+2.23%
OverviewShort InterestFilings
AVLNQT27Avalyn Pharma Inc. Common Stock·NASDAQ
26.17+2.23%

Latest SEC Filings

Form category
DescriptionFilingDocument
Sep 17, 20264Statement of changes in beneficial ownership
Sep 17, 20263Initial statement of beneficial ownership
Sep 16, 20268-KCurrent report
Aug 14, 2026SC 13GBeneficial ownership statement (passive)
Aug 12, 202610-QQuarterly report
Aug 12, 20268-KCurrent report
Aug 11, 2026SC 13GBeneficial ownership statement (passive)
Aug 06, 2026SC 13G/ABeneficial ownership statement (passive, amended)
Jul 01, 20268-KCurrent report
Jun 17, 20268-KCurrent report
Jun 03, 202610-QQuarterly report
Jun 03, 20268-KCurrent report
May 08, 2026SC 13DBeneficial ownership statement (active)
May 08, 2026SC 13DBeneficial ownership statement (active)
May 07, 2026SC 13GBeneficial ownership statement (passive)
May 05, 2026SC 13GBeneficial ownership statement (passive)
May 05, 20264Statement of changes in beneficial ownership
May 05, 20264Statement of changes in beneficial ownership
May 04, 20264Statement of changes in beneficial ownership
May 01, 20264Statement of changes in beneficial ownership
May 01, 20264Statement of changes in beneficial ownership
May 01, 20264Statement of changes in beneficial ownership
May 01, 20264Statement of changes in beneficial ownership
May 01, 20264Statement of changes in beneficial ownership
May 01, 20268-KCurrent report
#1 / 25 of 57
Page
▼
/ 3